Randomized Phase 2/3 Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)
Principal Investigator
Dr Mark Henry Tuthill
Contact us
Email: latephaseoncology@ouh.nhs.uk
IRAS number
1014270